Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,466 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Infection Control Clear all
Completed Phase 4 Interventional Results available

Post-Operative Colonization Rates of Femoral Nerve Catheters Treated With Chlorhexidine-Impregnated Patch

NCT01411891
View directory record Official record
Conditions
Catheter Infections, Spinal Catheter (Epidural) (Subdural); Complications, Infection or Inflammation
Interventions
Chlorhexidine impregnated patch (Biopatch)
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 28, 2018 · Synced Oct 23, 2026, 10:45 AM EDT
Recruiting Not applicable Interventional

AFFECT Study for Patients With Intraventricular Hemorrhage, Subarachnoid Hemorrhage, Subdural Hematoma, and Ventriculitis

NCT05649904
View directory record Official record
Conditions
Intraventricular Hemorrhage, Subarachnoid Hemorrhage, Subdural Hematoma, Ventriculitis
Interventions
IRRAflow with Active Fluid Exchange System, External Ventricular Drain
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

NCT01193478
View directory record Official record
Conditions
HCV Infection
Interventions
GS-5885, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
13
States / cities
Anaheim, California • Cypress, California • National City, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2013 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy

NCT00004978
View directory record Official record
Conditions
HIV Infections
Interventions
Recombinant interleukin-2 (rIL-2)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
78
States / cities
Los Angeles, California • Mill Valley, California • Oakland, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 2 Interventional

GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection

NCT01435226
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
GS-5885, GS-9451, tegobuvir, placebo to match tegobuvir, placebo to match RBV, Ribavirin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
37
States / cities
Tucson, Arizona • Anaheim, California • Beverly Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Oct 23, 2026, 10:45 AM EDT
Recruiting Phase 2 Interventional

Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis

NCT07285070
View directory record Official record
Conditions
Non-infectious Anterior Uveitis
Interventions
Tacrolimus ophthalmic solution
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
6
States / cities
Phoenix, Arizona • Miami, Florida • Waltham, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease

NCT00516321
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
eltrombopag, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
47
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Not applicable Interventional

RECOVER-ENERGIZE Platform Protocol

NCT06404047
View directory record Official record
Conditions
Long COVID, Long Covid19, Long Covid-19
Interventions
Personalized Cardiopulmonary Rehabilitation, Structured Pacing, Education, Usual Care
Behavioral · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Results available

Therapeutic Vaccine for HIV

NCT01859325
View directory record Official record
Conditions
HIV, Therapeutic Vaccine
Interventions
rVSV, IL-12 pDNA adjuvant, HIV-Mag pDNA, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 23, 2026, 10:45 AM EDT
Recruiting Not applicable Interventional

Reducing Overuse of Antibiotics With Decision Support

NCT06788093
View directory record Official record
Conditions
Lower Respiratory Tract Infection, Pneumonia, Asthma, Bronchiolitis, Viral
Interventions
ED Clinical Decision Support (CDS-ED), Transitions Clinical Decision Support (CDS-Tr)
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
6 Months to 17 Years
Enrollment
2,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Oakland, California • San Francisco, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 2 Interventional

A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS

NCT00001058
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Ethambutol hydrochloride, Clarithromycin, Rifabutin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
33
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 23, 2026, 10:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The SPOT-HPV Study

NCT05524025
View directory record Official record
Conditions
HPV Infection, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Salivary TTMV-HPV DNA Test, Blood TTMV-HPV DNA Test
Diagnostic Test
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Not listed Not applicable Interventional

Randomized Clinical Study Assessing NuShield Versus Standard of Care in Diabetic Foot Ulcers

NCT03855514
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
NuShield
Other
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years to 85 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Carlsbad, California • Fresno, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 3 Interventional

A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral/Oral Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia in AIDS

NCT00000715
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pentamidine isethionate, Sulfamethoxazole-Trimethoprim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
9
States / cities
New Orleans, Louisiana • Boston, Massachusetts • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 23, 2026, 10:45 AM EDT
Active, not recruiting Phase 1 Interventional

HepB mAb19 in Individuals With Chronic Hepatitis B Infection

NCT05856890
View directory record Official record
Conditions
Hepatitis b Virus, Hepatitis B
Interventions
HepB mAb19, Sterile Saline
Biological · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI

NCT02563106
View directory record Official record
Conditions
Clostridium Difficile, Clostridium Infections
Interventions
SYN-004, Placebo
Drug
Lead sponsor
Theriva Biologics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Little Rock, Arkansas • Torrance, California • DeLand, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vitamin D3 Supplementation to Prevent Respiratory Tract Infections

NCT04596657
View directory record Official record
Conditions
Respiratory Tract Infections, Covid19, Flu Like Illness
Interventions
Vitamin D supplementation
Dietary Supplement
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
877 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 8, 2023 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 4 Interventional Results available

Investigation of Microbiomes of Postmenopausal Women Looking for Outcomes and Response to Estrogen Therapy

NCT03996603
View directory record Official record
Conditions
Female Urogenital Diseases, Vaginal Atrophy, Postmenopausal Atrophic Vaginitis, Genitourinary Disease, Postmenopausal Symptoms
Interventions
Conjugated Estrogens Cream
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
55 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

NCT01641822
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI, Placebo to match AZLI, Tobramycin inhalation solution
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 62 more
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 23, 2026, 10:45 AM EDT
Terminated Phase 2 Interventional

Prevention of Infection Using a Topical Gentamicin-Collagen Sponge in Diabetic Patients With An Uninfected Foot Ulcer

NCT00658957
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
gentamicin-collagen sponge, placebo collagen sponge
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Pasadena, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Oct 23, 2026, 10:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immunopathogenesis of Chlamydia

NCT00607659
View directory record Official record
Conditions
CHLAMYDIA INFECTIONS
Interventions
No intervention, only observational
Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
11 Years to 21 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis

NCT02054156
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
azithromycin, placebo, Tobramycin solution for inhalation
Drug
Lead sponsor
Bonnie Ramsey
Other
Eligibility
6 Months to 18 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
45
States / cities
Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 23, 2026, 10:45 AM EDT
Recruiting Not applicable Interventional

A Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections

NCT06940622
View directory record Official record
Conditions
Recurrent UTIs, Recurrent Urinary Tract Infections, Recurrent Urinary Tract Infections in Women, Recurrent Urinary Tract Infection, Cystitis Recurrent, Cystitis Chronic, UTI, UTI - Urinary Tract Infection, UTI - Lower Urinary Tract Infection
Interventions
D-Mannose, Placebo
Dietary Supplement
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
55 Years to 85 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Not applicable Interventional Results available

Wound Infection Alexis Wound Retractor

NCT00323453
View directory record Official record
Conditions
Appendicitis
Interventions
Open appendectomy using Alexis Wound Retractor followed by standardized wound closure, Open appendectomy with standardized wound closure
Device · Procedure
Lead sponsor
Santa Barbara Cottage Hospital
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2018 · Synced Oct 23, 2026, 10:45 AM EDT